Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

GRI Bio Inc

GRI ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.84

▲ +1.66%

Market Cap $4.02M · Vol 17.23K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.02M

Micro Cap

Div Yield

N/A

EPS Growth

+96.39%

YoY

RSI (14)

45.42

Momentum

Beta

-1.13

vs Market

52W High

$64.12

97.18% below

52W Low

$1.37

32.12% above

Volume

17.23K

Avg 69.08K

P/B

0.57

Price-to-book

ROE

N/A

Return on equity

Free Float

99.63%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, GRI Bio Inc (GRI) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GRI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.15%

+6.36%

-20.69%

-28.68%

YTD

-73.37%

-96.58%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,956,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-166.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.57
P/FCF	N/A
EPS Growth	+96.39%
Outstanding Shares	2.19M

Technical Indicators

50-Day SMA	$1.74
200-Day SMA	$5.00
RSI (14)	45.42
Beta	-1.13
52-Week High	$64.12
52-Week Low	$1.37

Volume Today	17.23K
Avg Daily Volume (30D)	69.08K
Relative Volume	0.25x
Volatility (10D)	235.61
Volatility (30D)	176.11
Free Float	99.63%

Analyst Consensus

BUY

Current Price $1.84

Mean Target $153.50

52W Low$1.37 52W High$64.12

Current

Target

$1.37 $64.12

Current Analyst target

+8,242.39% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00XZQMLW5

ISINUS3622AW5029

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).